KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Goodwill for 6 consecutive years, with $162.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill changed N/A year-over-year to $162.0 million, compared with a TTM value of $162.0 million through Sep 2025, changed N/A, and an annual FY2024 reading of $148.9 million, up 185.99% over the prior year.
  • Goodwill was $162.0 million for Q3 2025 at Recursion Pharmaceuticals, up from $158.1 million in the prior quarter.
  • Across five years, Goodwill topped out at $162.0 million in Q3 2025 and bottomed at $801000.0 in Q2 2021.
  • Average Goodwill over 5 years is $65.5 million, with a median of $26.4 million recorded in 2021.
  • The sharpest move saw Goodwill changed 0.0% in 2021, then soared 6398.88% in 2023.
  • Year by year, Goodwill stood at $801000.0 in 2021, then changed by 0.0% to $801000.0 in 2022, then skyrocketed by 6398.88% to $52.1 million in 2023, then surged by 185.99% to $148.9 million in 2024, then grew by 8.85% to $162.0 million in 2025.
  • Business Quant data shows Goodwill for RXRX at $162.0 million in Q3 2025, $158.1 million in Q1 2025, and $148.9 million in Q4 2024.